ARTICLE | Clinical News

Ardelyx discontinuing hyperkalemia candidate

November 21, 2017 9:11 PM UTC

In a pipeline update Tuesday, Ardelyx Inc. (NASDAQ:ARDX) said it will discontinue development of hyperkalemia candidate RDX7675 after observing an unexpected, treatment-related side effect of reduced serum bicarbonate levels in a Phase II trial. The company said the side effect could limit the product's chronic use. Ardelyx said it expects the move to result in about $40 million in savings over the next two years.

Ardelyx said RDX7675 did significantly reduce serum potassium levels across all dose levels in the placebo-controlled Phase II trial in about 60 patients with hyperkalemia. The oral non-absorbed, potassium-binding polymer based on polystyrene sulfonate was also in a Phase III trial for the indication...

BCIQ Company Profiles

Ardelyx Inc.